Neuland Laboratories Ltd (NEULANDLAB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Neuland Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Audio Recording of the Earnings call conducted on November 3, 2026
Audio / Video · 04 Nov 2026, 1:25 am
Neuland Laboratories Releases Audio Recording of Q2/H1 Earnings Call Neuland Laboratories has made available the audio recording of its earnings call conducted on 3rd Nov'26 for the quarter and half year ended 30th Sep'26. The recording has been published on the company's official website in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Investor Presentation on the Financial Results of the Company for the quarter and half year ended September 30, 2026
Investor Presentation · 03 Nov 2026, 9:54 pm
Neuland Laboratories Reports Mixed Q2FY27 Results Amid Robust H1 Growth Neuland Laboratories reported standalone total income of ₹457.2 Cr for Q2FY27, down 11.4% YoY. EBITDA declined 33.4% YoY to ₹104.6 Cr, with margins contracting 754 bps YoY to 22.9% due to operating deleverage. PAT fell 47.0% YoY to ₹51.1 Cr, while diluted EPS stood at ₹39.9. Conversely, H1FY27 total income grew 35.6% YoY to ₹1,107.2 Cr, and PAT rose 80.2% YoY to ₹198.5 Cr. Net cash stood at ₹208.0 Cr. Active CMS projects reached 99, supported by ongoing capex in peptides and R&D.
Press Release on the Financial Results of the Company for the quarter and half year ended September 30, 2026
Press Release · 03 Nov 2026, 9:45 pm
Neuland Laboratories Reports Q2 FY27 Financial Results Neuland Laboratories reported a standalone Q2 FY27 revenue decline of 11.4% YoY to ₹457.2 Cr (-29.7% QoQ). EBITDA dropped 33.4% YoY to ₹104.6 Cr, with margins contracting 754 bps YoY to 22.9% due to operating deleverage. PAT fell 47.0% YoY to ₹51.1 Cr, while diluted EPS stood at ₹39.9. For H1 FY27, revenue rose 35.6% YoY to ₹1,107.2 Cr and PAT surged 80.2% YoY to ₹198.5 Cr. Working capital cycle improved to 104 days from 155 days. Capex reached ₹261 Cr, supporting R&D and peptide capacity expansions.
Disclosure under Regulation 30 of SEBI Listing Regulations
Others (Uncategorized) · 03 Nov 2026, 9:31 pm
Neuland Laboratories Reports Q2 Results and Approves ₹47.1 Crore Land Acquisition Neuland Laboratories approved Q2 results for the period ended 30th Sep'26, reporting consolidated revenue from operations of ₹44,965.69 lakhs compared to ₹51,427.31 lakhs in Q2 FY25 (YoY) and ₹64,157.71 lakhs in Q1 FY27 (QoQ). Consolidated net profit stood at ₹5,162.50 lakhs versus ₹9,685.39 lakhs in the year-ago quarter, with EPS at ₹40.24. Additionally, the Board approved a capital expenditure of ₹47.1 crores (inclusive of GST) funded entirely via internal accruals to acquire a 6-acre land parcel in Telangana for future capacity expansion.
Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026
Financial Result · 03 Nov 2026, 9:25 pm
Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 03 Nov 2026, 9:20 pm
Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026
Outcome · 03 Nov 2026, 9:18 pm
Neuland Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 44,966 (-12.6% YoY | -29.9% QoQ) ■ EBITDA: 9,756 (-37.3% YoY | -56.2% QoQ) ■ EBITDA Margin (%): 21.7 (-855 bps YoY | -1304 bps QoQ) ■ PAT: 5,163 (-46.7% YoY | -65.0% QoQ) ■ EPS (INR): 40.2 (-46.7% YoY | -65.0% QoQ)
Intimation of Loss of Share Certificate(s)
Others (Uncategorized) · 29 Oct 2026, 6:09 pm
Neuland Laboratories Reports Loss of Share Certificate Under Regulation 39(3) Pursuant to Regulation 39(3) of SEBI LODR Regulations, 2015, Neuland Laboratories reported the loss of a physical share certificate on 29th Oct'26. The intimation concerns shareholder Madan Mohan Singh (Folio No. 0008200) for 100 equity shares covering distinctive numbers 2823701 to 2823800. The shareholder has requested the issuance of an entitlement letter or direct credit of shares in lieu of the lost physical certificate.
Q2FY27 Earnings Call Intimation
Intimation · 03 Nov 2026, 5:30 pm
Neuland Laboratories Schedules Q2 FY27 Earnings Conference Call Neuland Laboratories Limited has scheduled its Q2 FY27 earnings conference call for 3rd Nov'26 at 17:30 IST. The API manufacturer operates cGMP facilities serving customers across nearly 80 countries, with a portfolio of over 100 APIs, 300+ developed processes, and 1,010+ global regulatory filings, including 75 active US DMFs.
NEULAND LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 03 Nov 2026, 5:30 am
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2026
Intimation · 03 Nov 2026, 5:30 am
Neuland Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve the unaudited Financial ....
Intimation · 03 Nov 2026, 5:30 am
Neuland Laboratories Board to Consider Q2 and H1 FY27 Results on 3rd Nov'26 Neuland Laboratories Limited has scheduled a meeting of its Board of Directors on 3rd Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half year ended 30th Sep'26. Additionally, pursuant to the company's Insider Trading Code, the trading window for dealing in equity shares remains closed from 1st Oct'26 until 48 hours following the declaration of the financial results.
We refer to our letter dated August 14, 2026 regarding the US FDA inspection conducted at our Unit 3 manufacturing facility and we would like to inform that the US FDA has issued an EIR ....
Others (Uncategorized) · 15 Oct 2026, 3:13 am
Neuland Laboratories Receives US FDA EIR for Unit 3 Manufacturing Facility Neuland Laboratories has received an Establishment Inspection Report (EIR) from the US FDA for its Unit 3 manufacturing facility located at Gaddapotharam Village, Sangareddy District. The inspection, conducted between 10th Aug'26 and 14th Aug'26, has been formally concluded as "closed" by the US FDA, clearing regulatory overhang for the manufacturing site.
Intimation about Schedule of Analyst / Institutional Investor Meeting on September 23 - 25, 2026
Intimation · 16 Sept 2026, 9:42 pm
Neuland Laboratories to Attend Goldman Sachs Global Healthcare CDMO Day in Singapore Neuland Laboratories management will participate in the Goldman Sachs Global Healthcare CDMO Day from 23rd Sep'26 to 25th Sep'26 in Singapore. The interactions will comprise group and one-on-one meetings with analysts and institutional investors, subject to exigencies.
Press Release
Press Release · 15 Sept 2026, 3:57 pm
Neuland Laboratories Accelerates Commercial Peptide Capacity Expansion Following Strong Revenue Growth Neuland Laboratories operationalized the first of four commercial peptide modules on 15th Sep'26, investing $30 million to add 7,000 L total reactor capacity (750 L SPPS, 6,250 L LPPS). Work on module two is advancing ahead of schedule, targeting up to 18,000 L capacity to capture expanding demand across obesity, metabolic, and oncology pipelines. Supported by 212 peptide specialists, this expansion follows a 116% YoY surge in Neuland’s latest quarterly revenues, driven by rising commercial contracts and clinical-stage projects.
Intimation about Schedule of Analyst / Institutional Investor Meeting on September 15, 2026 and September 17, 2026
Intimation · 09 Sept 2026, 11:37 pm
Neuland Laboratories Schedules Group Investor Meetings in Hyderabad Neuland Laboratories Limited announced that its management will participate in two upcoming group analyst and institutional investor meetings in Hyderabad. The company is scheduled to attend the Emkay Global Investors Meeting on 15th Sep'26, followed by the ICICI Securities - Hyderabad Healthcare Day on 17th Sep'26. The schedule and participant list remain subject to change based on operational exigencies.
Disclosure under Regulation 30 of SEBI Listing Regulations
Others (Uncategorized) · 07 Sept 2026, 10:55 pm
Neuland Laboratories Approves ₹126 Crore Capex for Land Acquisition Neuland Laboratories' Board approved a capital expenditure of ₹126 crore on 7th Sep'26 to acquire approximately 134 acres of land at Auro Industrial City, Kakinada, Andhra Pradesh, for future expansion. The acquisition will be funded entirely through internal accruals. Additionally, the company holds a right of first refusal to acquire a contiguous parcel of around 66 acres at a later date, potentially scaling the total land footprint at the location to approximately 200 acres.
Announcement under Regulation 30 (LODR) - Credit Rating
Others (Uncategorized) · 26 Aug 2026, 2:09 am
Neuland Labs Outlook Upgraded to 'Positive' by CRISIL CRISIL has revised Neuland Laboratories' long-term rating outlook to 'Positive' while reaffirming the rating at 'CRISIL A+'. This action, announced on Aug 25, '26, signals potential for a future rating upgrade based on improving credit fundamentals. The short-term rating was also reaffirmed at 'CRISIL A1'. This development is a positive credit signal for the company, suggesting enhanced financial stability and operational performance.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Malabar India Fund Ltd
Acquisition/ Disposal of Shares · 17 Aug 2026, 7:33 pm
Malabar India Fund Sells Stake in Neuland Laboratories Malabar India Fund Ltd sold 272,634 equity shares of Neuland Laboratories Ltd via open market transactions between 10 Aug '24 and 14 Aug '26. The sale represents 2.12% of the company's total voting capital. Following the sale, Malabar India Fund's shareholding in Neuland Labs has decreased from 7.18% (921,371 shares) to 5.06% (648,737 shares). Malabar India Fund does not belong to the promoter group. The transaction was disclosed under SEBI SAST Regulations, 2011, on 14 Aug '26.
Intimation regarding completion of US FDA Inspection
Others (Uncategorized) · 15 Aug 2026, 12:22 am
Neuland Labs Receives Form 483 with One Observation for Unit 3 Neuland Laboratories' Unit 3 manufacturing facility in Sangareddy underwent a US FDA inspection from 10th to 14th Aug'26. The inspection concluded with a Form 483 issuance containing a single observation. This observation pertains to procedural improvements for water and environmental monitoring, specifically to include organisms not listed in the United States Pharmacopeia (USP). The company intends to submit its response to the FDA within the stipulated timelines.
Transcript of the Earnings Call conducted on August 5, 2026
Transcript · 11 Aug 2026, 12:25 am
Intimation about Schedule of Analyst / Institutional Investor Meeting on August 12, 2026
Intimation · 07 Aug 2026, 7:14 pm
Neuland Labs to Attend Emkay Confluence 2026 Investor Event Neuland Laboratories management will participate in the Emkay Confluence 2026 event in Mumbai on 12 Aug'26. The meeting will consist of group and one-on-one sessions with analysts and institutional investors. The company notes that the schedule and participant list for the event are subject to potential changes. This intimation was filed under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements.
Audio Recording of the Earnings call conducted on August 5, 2026
Audio / Video · 06 Aug 2026, 3:51 am
Neuland Labs Posts Q1 FY27 Earnings Call Audio Recording Neuland Laboratories published the audio recording of its earnings call held on 5th Aug'26, discussing financial results for the quarter ended 30th Jun'26. The company filed the update with the BSE and NSE exchanges, providing a weblink to the recording for investors and stakeholders. The disclosure is compliant with SEBI regulations.
Disclosure under Regulation 30 of SEBI Listing Regulations - Enhancement of manufacturing capacity
Others (Uncategorized) · 05 Aug 2026, 10:07 pm
Neuland Labs Reports Q1 Results, Announces Capex and Gland Pharma Partnership Neuland Laboratories approved Q1FY27 results on 05 Aug'26, posting a consolidated PAT of ₹147.67 crore on revenues of ₹641.58 crore. The board also sanctioned a ₹39.8 crore capex to add 18 KL capacity at its Unit 1, funded by internal accruals over 6-7 months. Separately, Neuland will provide a ₹40 crore corporate guarantee for Gland Pharma, which is establishing a dedicated sterile API manufacturing suite for Neuland. This strategic CDMO partnership aims to add 1,400 kg of annual capacity for sterile APIs.
Disclosure under Regulation 30 of SEBI Listing Regulations - Execution of deed of Corporate Guarantee
Others (Uncategorized) · 05 Aug 2026, 10:01 pm
Neuland Labs Q1FY27 Net Profit Surges YoY; Announces Capex and Gland Pharma Partnership Neuland Labs reported a consolidated net profit of ₹147.67 crores for Q1FY27, up significantly from ₹13.90 crores YoY, on revenues of ₹641.58 crores (+119% YoY). The Board approved a ₹39.8 crore internally-funded capex to add 18 KL capacity at Unit 1 within 6-7 months. The company also entered a strategic partnership with Gland Pharma for sterile API manufacturing, supported by a ₹40 crore corporate guarantee to Gland Pharma for establishing a dedicated manufacturing suite. This creates a contingent liability but has no immediate financial impact.